US FDA approves Amgen and Allergan's Avastin biosimilar

By Gareth Macdonald contact

- Last updated on GMT

iStock/MarianVejcik
iStock/MarianVejcik

Related tags: Food and drug administration, Monoclonal antibodies

US regulators have approved Amgen Inc’s Mvasi (bevacizumab-awwb), a biosimilar version of Roche’s monoclonal antibody (mAb) cancer treatment Avastin (bevacizumab). 

The decision​, which is in line with a recommendation made by the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) in July​, clears Mvasi for the treatment of the same cancers as Avastin.

The approval states that the mAb is a biosimilar but not interchangeable with the Roche drug.

Amgen developed Mvasi in collaboration with Allergan under a deal signed in 2010. The agreement covered the development of four cancer biosimilars.

An Amgen spokeswoman told us "In the collaboration with Allergan, Amgen has primary responsibility for the development, manufacture and initial commercialization of the products; whereas Allergan will provide funding over the course of development as well as expertise gained in the commercialization and marketing of products​."

She declined to comment when asked when Mvasi would be launched in the US or if it would be sold at a discounted rate relative to the innovator drug.

"The FDA’s approval is an exciting step towards recognizing Mvasi as an important treatment option for certain patients with cancer. The patent information exchange under the regulatory scheme governing biosimilars (the BPCIA) is ongoing. We have not commented on launch timelines​."

In December​, Amgen announced that it Mvasi – previously known as ABP 215 – submitted for review by the European Medicines Agency (EMA).

Related news

Show more

Related products

show more

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 22-Jul-2019 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Related suppliers

Follow us

Products

View more

Webinars